News

Lexaria Bioscience Announces Warrant Issuance

Kelowna, British Columbia– March 16, 2020 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company”), a global innovator in drug delivery platforms, announces that on March 16, 2020 it…

Lexaria Provides Update on Two Licensed Clients

Kelowna, British Columbia– March 4, 2020 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that it has successfully…

Lexaria Awards Options

Kelowna, British Columbia– February 7, 2020 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that it has issued…

Letter From the CEO (Long Version)

Lexaria Bioscience Corp (“Lexaria”, or the “Company”) is a global biotech leader in developing and implementing advanced technologies to better deliver Active Pharmaceutical Ingredients (“APIs”) into the human body for…

Lexaria Provides Strategic Update from CEO

Kelowna, British Columbia– January 9, 2020 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces the following strategic update.…